Stable, recombinant AequoScreen® cell line expressing aequorin and the Apelin receptor (APJ), human recombinant in CHO-K1 host cells.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Cell Line Terms and Conditions must be accepted before orders are placed. Additional agreement needed for commercial use.
PerkinElmer’s AequoScreen® double transfected cell lines are provided in two vials of frozen cells, each containing ∽2.5 x 106 cells. Detailed product information as well as recommended cell culture conditions and validation assay date are available for each cell line.
The AequoScreen technology is a generic GPCR technology that can be used with Gs, Gi, and Gq-coupled GPCRs and calcium coupled ion channels. Following receptor stimulation, increases in intracellular calcium enable measurement of the resulting flash luminescence signal.
PerkinElmer’s AequoScreen cell lines require accepted cell line Terms and Conditions prior to order processing. Additional agreement needed for commercial use. Contact us using the Request More Information button above for additional information regarding required documentation.
|Assay Target Class||GPCR|
|Assay Target Type||Cell line|
|Assay Validated||Calcium Luminescence|
|G-Alpha Coupling Protein||Ga16|
|G-Alpha Natural Receptor||Gi/Go|
|Product Brand Name||AequoScreen|
|Second Messenger Release||Calcium flux|
|Shipping Condition||Dry Ice|
|Special Ordering Information||Requires accepted Terms and Conditions. Additional agreement needed for commercial use.|
|Unit Size||5 million cells|
Aequorin is a photo protein originating from the jellyfish Aequorea Victoria. The apo-enzyme (apoaequorin) is a 21 kD protein, which requires a hydrophobic prosthetic group, coelenterazine, to be converted to aequorin,the active form of the enzyme. This enzyme possesses 3 calcium binding sites which ...
Life science researchers are always working toward the next breakthrough discovery. For scientists working on GPCRs, speed is everything. And when it comes to drug discovery, overcoming the challenge of decreasing assay development time and accelerating your research, is necessary for success.